Tessa Rademaker‐Havinga
A5031006058- Coronary Interventions and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Cerebrovascular and Carotid Artery Diseases
- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Lipoproteins and Cardiovascular Health
- Cardiac Valve Diseases and Treatments
- Mechanical Circulatory Support Devices
- Pharmaceutical Economics and Policy
- Transplantation: Methods and Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Health and Mental Health
- Health Systems, Economic Evaluations, Quality of Life
- Blood Pressure and Hypertension Studies
- Cardiovascular Health and Disease Prevention
- Viral Infections and Immunology Research
- Peripheral Artery Disease Management
Cardialysis (Netherlands)
2011-2023
University of Zurich
2020
MedStar Washington Hospital Center
2018
<h3>Importance</h3> The role of aspirin as part antiplatelet regimens in acute coronary syndromes (ACS) needs to be clarified the context newer potent P2Y12 antagonists. <h3>Objective</h3> To evaluate benefit and risks addition ticagrelor among patients with ACS beyond 1 month after percutaneous intervention (PCI). <h3>Design, Setting, Participants</h3> This is a nonprespecified, post hoc analysis GLOBAL LEADERS, randomized, open-label superiority trial comparing 2 treatment strategies PCI....
Importance Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase in ischemic events patients at high risk (HBR) undergoing percutaneous coronary intervention (PCI). Objectives To evaluate the association of sex comparative effectiveness abbreviated vs standard DAPT HBR. Design, Setting, and Patients This prespecified subgroup analysis followed Management High Bleeding Risk Post Bioresorbable Polymer Coated Stent Implantation With an Standard Regimen (MASTER DAPT)...
AimsTo compare the long-term clinical safety between two drug-eluting stents with different healing characteristics in Patient Related Outcomes Endeavour (E-ZES) vs. Cypher (C-SES) Stenting Trial (PROTECT). At 3 years, there was no difference primary outcome of definite or probable stent thrombosis other main secondary outcomes consisting composite death myocardial infarction (MI). Prespecified 4-year follow-up analysed.
AimTo investigate the putative modifying effect of dual antiplatelet therapy (DAPT) use on incidence stent thrombosis at 3 years in patients randomized to Endeavor zotarolimus-eluting (E-ZES) or Cypher sirolimus-eluting (C-SES).
Antiplatelet treatment in the elderly post percutaneous coronary interventions (PCI) remains a complex issue. Here we report results of pre-specified subgroup analysis GLOBAL LEADERS trial evaluating long-term safety and cardiovascular efficacy ticagrelor monotherapy among patients categorised according to cut-off value 75 years age.This was randomised (n=15,991), comparing 23-month (after one month DAPT) with reference (12-month DAPT followed by 12 months aspirin). Among (>75 years;...
The aim of this study was to evaluate the impact 23-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) on rates patient-oriented composite endpoints (POCE) and net adverse clinical events (NACE).The site-reported Academic Research Consortium (ARC)-2 defined POCE (all-cause death, any stroke, myocardial infarction or revascularisation) NACE (POCE bleeding type 3 5 according Bleeding ARC [BARC]) were reported up two...
To evaluate long-term safety and efficacy of ticagrelor monotherapy in patients undergoing percutaneous coronary interventions (PCIs) relation to chronic obstructive pulmonary disease (COPD) at baseline the occurrence dyspnoea reported as adverse event (AE) that may lead treatment non-adherence.This is a non-prespecified, post hoc analysis randomized GLOBAL LEADERS trial (n = 15 991), comparing experimental strategy 23-month following 1-month dual antiplatelet therapy (DAPT) after PCI with...
The prevalence of factors that are associated with an increased risk stent thrombosis (ST), including smoking, diabetes mellitus, and small size, is different in women men who underwent percutaneous coronary intervention. Thus, gender may potentially modify the relation between type incidence ST during long-term follow-up. We explored data Patient Related Outcomes With Endeavor Versus Cypher stenting Trial (PROTECT) to evaluate this hypothesis. PROTECT randomized 2,061 6,648 intervention for...
To validate a simplified core laboratory intravascular ultrasound (IVUS) analysis method based on frames with visually determined minimal lumen areas (MLAs) as compared comprehensive (per frame) method.IVUS-guided percutaneous coronary intervention has proven to be superior angiography-guided stenting. In clinical practice, cross-sections MLA are measured determine lesion severity or stent area (MSA), however, its accuracy not been per frame method.A total of 50 stented segments anonymized...
Purpose: PROTECT is the largest randomized trial to compare long-term safety of 2 DES with different antiproliferative properties: Endeavor zotarolimus-eluting stent (E-ZES) and Cypher sirolimus-eluting (C-SES). We analysed predictors combined late (L: >30d-1yr) very (VL: >1yr) definite (D) thrombosis (ST) L/VL definite/probable (D/P) ST at 3 years. Methods: There were 8709 patients from 36 countries in 2007/8. Categorical continuous variables time dependent variable dual antiplatelet...